Search

Search Constraints

You searched for: Author/Creator Hertzberg, Mark S.

Search Results

1. A Phase 1 study of the safety, pharmacokinetics and anti-leukemic activity of the anti-CD123 monoclonal antibody CSL360 in relapsed, refractory or high-risk acute myeloid leukemia. Issue 5 (May 2015)

2. Corrigendum to "KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study" [Leuk. Res. 50 (Nov) (2016) 123–131. PubMed PMID: 27736729]. (August 2017)

3. KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study. (November 2016)